Explore the fast-moving world of Latin American clinical research.
first-in-human · clinical trial · clinical research · regulatory · ANVISA · ICH
> Explore the fast-moving world of Latin American clinical research. In this edition: regulatory harmonization is smoothing pathways for innovation, Mexico pumps $400M into its MedTech industry, and ANVISA enforcement signals strict safety standards.
Regulatory harmonization is smoothing pathways for innovation. Mexico pumps $400M into its MedTech industry, fueling growth. ANVISA enforcement signals strict safety standards.
Catch the latest insights and stay ahead of the curve. 👇
A quiet but powerful shift is underway across Latin America's regulatory landscape. Health authorities in the region are deepening engagement with the International Council for Harmonisation (ICH), strengthening alignment with globally recognized technical and clinical standards.
While often overlooked, regulatory harmonization can have a profound impact on how innovation moves from development to market. As Latin American agencies adopt internationally accepted frameworks, the region's role in global clinical development continues to expand.
Why It Matters: Greater alignment with ICH standards reduces barriers for international sponsors, streamlines review timelines, and enhances the credibility of clinical data generated in the region. Latin America's regulatory convergence is positioning the region as a more strategic partner in global development programs.
Mexico's medical device industry is expanding rapidly, committing US$400 million to enhance manufacturing capabilities and strengthen its role as a leading healthcare hub in Latin America. The investment reflects growing confidence in the country's ability to support advanced medical technology and innovation.
Funds will focus on expanding facilities, improving supply chains, and leveraging skilled talent, reinforcing Mexico's attractiveness for global healthcare development. This surge in investment also signals broader opportunities for research, development, and clinical operations.
Key Takeaways:
Significant capital commitment signals confidence in Mexico's MedTech future Expanded manufacturing and supply chain capabilities strengthen regional competitiveness Broader investment momentum creates new pathways for clinical research and innovation
Does your company need accelerated first-in-human clinical trial results?
Overcome the complex landscape of first-in-human clinical trials with confidence. Whether you're advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Leverage 20+ years of expertise across Medtech, Biopharma, and Radiopharma first-in-human trials Navigate Latin America's regulatory environment and access high-quality research sites Get tailored support for study design, approvals, site selection, and patient recruitment
Bring your innovations to market faster with Latin America's first-in-human trial experts.
Schedule your first-in-human trial consultation at
The pivotal ROUTE90 study of ABK's Eye90 Y-90 microspheres for primary liver cancer has completed enrollment, marking a significant step forward in interventional oncology research. The therapy, designed to target liver tumors with precision, represents an innovative approach in radiopharmaceutical development.
Completion of enrollment brings the study closer to evaluating the treatment's safety and effectiveness, a critical phase for advancing novel therapies in oncology. This milestone underscores the momentum in radiopharma research and highlights how targeted therapies are moving through pivotal clinical stages.
Why It Matters: As targeted radiopharmaceutical therapies advance through pivotal stages, the ROUTE90 enrollment completion signals growing confidence in precision oncology approaches. Liver cancer remains an area with significant unmet needs, and innovative treatments like Y-90 microspheres represent the next frontier in interventional oncology.
Proper reporting of serious adverse events (SAEs) is essential for protecting participants and maintaining the integrity of clinical trials. Clear processes for identifying, documenting, and communicating SAEs help ensure ethical oversight and compliance with regulatory requirements, particularly in early-phase studies where risks are less predictable.
Timely and accurate SAE reporting allows research teams to detect potential safety signals, respond appropriately, and maintain the credibility of trial data. By following best practices, teams can safeguard participants, support regulatory confidence, and enable smoother trial execution.
Key Focus Areas:
Standardized identification and documentation of serious adverse events Timely communication with regulatory authorities and ethics committees Best practices for maintaining data integrity and participant safety Strengthened compliance frameworks for early-phase clinical studies
Pablo Yarza highlights the critical role of bioinformatics and data curation in modern clinical research. As trials become increasingly complex and data-intensive, effectively managing and analyzing clinical and molecular datasets is essential for generating accurate insights and guiding study decisions.
Why It Matters: Efficient data curation supports better trial design, patient stratification, and outcome analysis, helping research teams identify meaningful patterns and improve study quality. Integrating bioinformatics into clinical operations accelerates development while ensuring high standards of accuracy and compliance.
Brazil's health regulator, ANVISA, has taken enforcement action on consumer health products, sending a clear signal about the country's commitment to safety and quality standards. The action underscores the importance of regulatory vigilance across Latin America's healthcare and wellness sectors.
With agencies like ANVISA actively monitoring products, companies operating in the region face a growing emphasis on compliance and quality. Such enforcement highlights the evolving regulatory landscape and the need for rigorous safety practices across Latin America.
Key Takeaways:
ANVISA enforcement underscores Brazil's commitment to consumer protection Companies operating in Latin America face increasing compliance expectations Regulatory vigilance reinforces the importance of quality-first strategies in the region
Latin America's regulatory convergence with ICH is expanding global clinical development pathways Mexico's $400M MedTech investment signals growing confidence in the region's healthcare capabilities The ROUTE90 enrollment milestone advances precision oncology in liver cancer treatment SAE reporting best practices remain essential for early-phase trial integrity Bioinformatics integration is accelerating smarter, more efficient clinical trial operations ANVISA enforcement reinforces Brazil's commitment to safety and regulatory standards
← All Global Trial Accelerators editions · Contact bioaccess®